NOD IL-2Rγnull mice were obtained from Charles River Laboratories (Sulzfeld, Germany). Mice were kept under specific pathogen-free conditions in individually ventilated cages in a facility controlled according to the Federation of Laboratory Animal Science Association (FELASA) guidelines. Following engraftment (day 1) mice were pre-sensitized by rectal application of 150 µl of 10% ethanol on day 8 using a 1 mm cat catheter (Henry Schein, Hamburg, Germany). The catheter was lubricated with Xylocaine©Gel 2% (AstraZeneca, Wedel). The rectal application was performed under general anesthesia using 4% isoflurane. Post application mice were kept at an angle of 30° to avoid ethanol dripping. On day 15 and 18 mice were challenged by rectal application of 50% ethanol following the protocol of day 8. Mice were sacrificed on day 21. Pitrakinra (10 µg in 0.5% Methylcellulose, 0.05% TWEEN 80 in PBS) [34 (link)] was applied on day 7–9 and 14–21. Sterile Saline (B. Braun Melsungen AG, Germany) served as a control. Infliximab, [6 mg/kg (Remicade©, Janssen The Netherlands)] and isotype control (30 µg in 200 µl PBS, Morphosys AG, Planegg, Germany) were applied on day 7 and 14. All treatments were applied intraperitoneally.
Free full text: Click here